drugset / Trial / NCT07514832
VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, prospective, single-arm clinical study designed to evaluate the efficacy and safety of the VA-CIG regimen (venetoclax combined with azacitidine, idarubicin, low-dose cytarabine and granulocyte colony-stimulating factor \[G-CSF\]) as induction therapy for previously untreated patients with fit acute myeloid leukemia (AML) who are eligible for intensive chemotherapy. This study aims to evaluate the efficacy and safety of the VA-CIG regimen in the target patient population.
Timeline
- Start
- 2026-04-15
- Primary completion
- 2028-04-01
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Idarubicin | Small molecule | 6 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Background | G-CSF | Unknown | 200 ug/m2 | — |